IL33 and neoplasm: Their pro-tumor activities can be curtailed by targeting cytokine signals (like IL-25) or reprogramming their inhibitory checkpoints (like PD-1), while their anti-tumor capacities can be harnessed by combining IL-33-based activation with checkpoint inhibitors.